Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + EP as first-line and maintenance therapy for advanced high-grade neuroendocrine tumors
ChiCTR2300076887Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib, etoposide and cisplatin in apudoma (NET), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibetoposidecisplatin
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2300076887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076887.